Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Original) A stable pharmaceutical composition of erythropoietin (EPO), wherein the composition comprises:

a. a therapeutically effective amount of EPO
b. a pharmaceutically acceptable pH buffering system,
c. a poloxamer polyol, and
d. a polyhydric alcohol.

Claim 2. (Original) The composition according to claim 1, wherein the composition is free of additives derived from human and/or animal origin.

Claim 3. (Currently amended) The composition according to claim 1 ~~or 2~~, wherein the composition is ~~optionally~~ further comprises

e. an isotonifying agent and/or
f. one or more pharmaceutically acceptable excipient(s).

Claim 4. (Currently amended) The composition of ~~any one of~~ claims 1 ~~to 3~~, wherein the composition is aqueous.

Claim 5. (Currently amended) The composition of ~~any one of~~ claims 1[[to 4]], wherein the pharmaceutical quantity of EPO is formulated to provide a quantity per dose in the range of about 500 to about 100000 IU EPO.

Claim 6. (Original) The composition of claim 5, wherein the pharmaceutical quantity is formulated to provide a quantity per dose selected form the group consisting of about 1000 IU, about 2000IU, about 3000 IU, about 4000 IU, about 10000 IU, about 20000 IU, about 25000 IU, about 40000 IU, about 50000 IU, about 60000 IU and about 100000 IU.

Claim 7. (Currently amended) The composition of ~~any one of~~ claims 1 ~~to 6~~, wherein the pH buffering system provides a pH range from about 6 to about 8.

Claim 8. (Original) The composition of claim 7, wherein the pH buffering system provides a pH range from about 6.8 to about 7.5.

Claim 9. (Original) The composition of claim 7, wherein the pH buffering system provides a pH of about 7.0.

Claim 10. (Currently amended) The composition of ~~any one of~~ claims 1 ~~to 9~~, wherein the pH buffering system is phosphate buffer.

Claim 11. (Currently amended) The composition of ~~any one of~~ claim~~s~~ 1 ~~to 10~~, wherein the poloxamer polyol is selected from the group of non-ionic surface active agents.

Claim 12. (Original) The composition of claim 11, wherein the poloxamer polyol is Pluronic F68.

Claim 13. (Original) The composition of claim 11, wherein the poloxamer polyol is comprised in a range of about 0.05% to about 0.5%.

Claim 14. (Original) The composition of claim 11, wherein the concentration of poloxamer polyol is about 0.1%.

Claim 15. (Currently amended) The composition of ~~any one of~~ claim~~s~~ 1 ~~to 14~~, wherein polyhydric alcohol is selected from the group comprising glycerol, sorbitol, mannitol and/or xyliol.

Claim 16. (Original) The composition of claim 15, wherein the polyhydric alcohol is glycerol.

Claim 17. (Original) The composition of claim 15, wherein the concentration of polyhydric alcohol is in the range of about 0.1% to about 10%.

Claim 18. (Original) The composition of claim 15, wherein the concentration of polyhydric alcohol is in the range of about 2% to about 5%.

Claim 19. (Currently amended) The composition of ~~any one of~~ claim~~s~~ 1 ~~to 18~~, wherein said isotonifying agent is selected from the group consisting of inorganic salts.

Claim 20. (Original) The composition of claim 19, wherein said isotonifying agent is NaCl.

Claim 21. (canceled)

Claim 22. (canceled)